Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Reperfusion injury is caused due to the damage in the tissue, which occurs due to the lack of blood supply. Examples of reperfusion injury include brain damage after stroke and many others, where reperfusion therapy leads to flow of blood in the tissue which results in inflammation and oxidative damage due to oxidative stress. Reperfusion injury can be treated by therapeutic hypothermia, hydrogen sulphide treatment, cyclosporins, stem cell therapy, and others. Furthermore, delay in reperfusion therapy results in oxidative damage.
Global Reperfusion Treatment Market – Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic is expected to hamper the global reperfusion treatment market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted majorly due to the COVID-19 pandemic. Many clinical trials have been suspended during the pandemic. In order to restart the clinical trials, the U.S. Food and Drug Administration (FDA) released guidelines during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency. The appendix of the guidelines also provide answers to some general questions, which the U.S. Food and Drug Administration (FDA) received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency. The above guidelines are also applicable for conducting the clinical trials for testing the safety and efficacy of the drugs for the reperfusion injury. Thus, the COVID – 19 pandemic is expected to decrease the growth of the reperfusion treatment market over the forecast period.
The global reperfusion treatment market is estimated to be valued at US$ 1,293.6 million in 2020 and is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).
Figure 1: Global Reperfusion Treatment Market Share (%) Analysis, By Treatment Type 2020
Increasing prevalence of coronary heart dis ease is expected to drive the growth of the global reperfusion treatment market during the forecast period.
The rising incidence of coronary artery disease (CAD) or ischemic heart disease (IHD) is a major factor which is expected to drive the market growth. The CAD or IHD is caused due to the buildup of cholesterol and fatty deposits on the inner walls of the arteries, which may lead to the reduction of blood flow to the heart cells. This condition may lead to ischemia, myocardial infraction or sudden cardiac arrest. Moreover, medicines approved from the regulatory authorities are not available in the market for the treatment of ischemia/reperfusion injury. According to the National Center for Biotechnology Information (NCBI), 2020, in 2017, globally, around 126 million people suffered from ischemic heart disease (1,655 per 100,000), which constituted to 1.72% of the total world population.
Investments and expansion of production facility by market players are expected to boost growth of the global reperfusion treatment market during the forecast period.
Market players are focusing on facility expansions in order to strengthen their product portfolio. For instance, on March 9, 2020, Pharming Group NV received the Food and Drug Administration (U.S. FDA) approval for its new production facility in the Netherlands for the production of the starting material required for manufacturing of RUCONEST. RUCONEST is a C1-esterase inhibitor, which is plasma free and is proven to help treat hereditary angioedema (HAE) attacks. Furthermore, on January 21, 2020, Pharming Group NV received the European Medicines Agency (EMA) approval for the production facility for RUCONEST in Europe.
Reperfusion Treatment Market Report Coverage
||Market Size in 2020:
||US$ 1,293.6 Mn
|Historical Data for:
||2017 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 1,758.6 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Treatment Type: Therapeutic Hypothermia, Cyclosporin, Stem cell Therapy, Hydrogen Sulphide Treatment, Others.
- By Injury Type: Heart Injury, Kidney Injury, Intestine Injury, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others.
Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.
- Increasing prevalence of cardiovascular diseases
- Expansion of production facilities
|Restraints & Challenges:
- Multiple organ failure during the reperfusion treatment
Global Reperfusion Treatment Market – Restraints
There are some side effects associated with the treatment, which are expected to restrain the global reperfusion treatment market during the forecast period. Ischemia reperfusion causes the mediator to infiltrate other tissues, which leads to Multiple Organ Dysfunction Syndrome (MODS). For instance, according to an article published in the International Institute of Anticancer Research in 2019, Multiple Organ Dysfunction Syndrome (MODS) was the leading cause of mortality globally and the incidence of MODS ranged from 25-40%. Furthermore, according to the Critical Care Nephrology Journal 2019, the pediatric multiple organ dysfunction syndrome (MODS) epidemiology ranges from 10% to 50% of the children admitted to the pediatric intensive care unit.
Global Reperfusion Treatment Market – Regional Analysis
On the basis of region, the global reperfusion treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to dominate the global reperfusion treatment market during the forecast period owing to research and development in the region. For instance, in November 2019, Faraday Pharmaceuticals announced positive results from phase II clinical trials of FDY-5301 for ischemia reperfusion injury treatment, following a STEMI heart attack. FDY-5301 is a formulated, patented, elemental reducing agent that contains sodium iodide. It destroys the hydrogen peroxide that is naturally generated as a response to acute ischemia reperfusion injury and also contributes to loss of muscle function and mass.
Europe is an emerging reperfusion treatment market owing to the funding provided for research and development by regulatory authorities. For instance, in February 2019, Balmes Transplantation SAS received around US$ 605,597 million from the European Regional Development Fund (ERDF) for its research program REMEDIRA for developing combinations of repurposed drugs against kidney ischemia-reperfusion injury (IRI).
Figure 2: Global Reperfusion Treatment Market Value (US$ Mn), by Region, 2020
Global Reperfusion Treatment Market - Competitive Landscape
Some of the key players operating in the global reperfusion treatment market are Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.